Lotte Steuten1, Bernardo Goulart1,2, Neal J Meropol3,4, Daryl Pritchard5, Scott D Ramsey1. 1. Fred Hutchinson Cancer Research Center, Seattle, WA. 2. Seattle Cancer Care Alliance, Seattle, WA. 3. Flatiron Health, New York, NY. 4. Case Western Reserve University, Cleveland, OH. 5. Personalized Medicine Coalition, Washington, DC.
Abstract
PURPOSE: Compared with single-marker genetic testing (SMGT), multigene panel sequencing (MGPS) has the potential to identify more patients with cancer who could benefit from targeted therapies, but the effects on outcome and total cost of care are uncertain. Our goal was to estimate the clinical and cost effectiveness of MGPS versus SMGT among patients with advanced non-small-cell lung cancer (aNSCLC). METHODS: Patients with aNSCLC-stage IIIB or metastatic-who were diagnosed between 2011 and 2016 were identified from the Flatiron Health database. After stratifying patients into MGPS or SMGT cohorts, we analyzed the percentage of patients who received targeted treatment, survival, and total costs of care. SMGT included epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase testing. MGPS also allowed for the detection of BRAF, RET, ROS1, HER2, and MET mutations. Cost data sources were the Centers for Medicare & Medicaid Services Fee Schedule and 2017 average sales price drug cost. We estimated the incremental cost-effectiveness ratio from a US payer perspective over a lifetime horizon using a decision model. RESULTS: We identified 5,688 patients with aNSCLC who received MGPS (n = 875) or SMGT (n = 4,813), of which 22% tested positive for epidermal growth factor receptor (18.5% MGPS; 17.3% SMGT) or anaplastic lymphoma kinase (3.59% MGPS; 3.78% SMGT). Among MGPS-tested patients, an additional 8% were found to have BRAF, RET, ROS1, HER2, or MET mutations. Of MGPS-tested patients, 21% received treatments that were targeted to the specific mutations versus 19% with SMGT. Expected survival was 1.14 life years (LYs) in SMGT versus 1.20 LYs in MGPS. Lifetime total costs were $8,814 higher per patient for MGPS. The incremental cost-effectiveness ratio of MGPS versus SMGT was $148,478 per LY gained. CONCLUSION: On the basis of data from a nationwide oncology patient database, MGPS is shown to have moderate cost effectiveness compared with SMGT in patients with aNSCLC.
PURPOSE: Compared with single-marker genetic testing (SMGT), multigene panel sequencing (MGPS) has the potential to identify more patients with cancer who could benefit from targeted therapies, but the effects on outcome and total cost of care are uncertain. Our goal was to estimate the clinical and cost effectiveness of MGPS versus SMGT among patients with advanced non-small-cell lung cancer (aNSCLC). METHODS:Patients with aNSCLC-stage IIIB or metastatic-who were diagnosed between 2011 and 2016 were identified from the Flatiron Health database. After stratifying patients into MGPS or SMGT cohorts, we analyzed the percentage of patients who received targeted treatment, survival, and total costs of care. SMGT included epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase testing. MGPS also allowed for the detection of BRAF, RET, ROS1, HER2, and MET mutations. Cost data sources were the Centers for Medicare & Medicaid Services Fee Schedule and 2017 average sales price drug cost. We estimated the incremental cost-effectiveness ratio from a US payer perspective over a lifetime horizon using a decision model. RESULTS: We identified 5,688 patients with aNSCLC who received MGPS (n = 875) or SMGT (n = 4,813), of which 22% tested positive for epidermal growth factor receptor (18.5% MGPS; 17.3% SMGT) or anaplastic lymphoma kinase (3.59% MGPS; 3.78% SMGT). Among MGPS-tested patients, an additional 8% were found to have BRAF, RET, ROS1, HER2, or MET mutations. Of MGPS-tested patients, 21% received treatments that were targeted to the specific mutations versus 19% with SMGT. Expected survival was 1.14 life years (LYs) in SMGT versus 1.20 LYs in MGPS. Lifetime total costs were $8,814 higher per patient for MGPS. The incremental cost-effectiveness ratio of MGPS versus SMGT was $148,478 per LY gained. CONCLUSION: On the basis of data from a nationwide oncology patient database, MGPS is shown to have moderate cost effectiveness compared with SMGT in patients with aNSCLC.
Authors: Madison M Wempe; Mark D Stewart; Daniel Glass; Laura Lasiter; Diana Merino Vega; Nisha Ramamurthy; Jeff Allen; Ellen V Sigal Journal: Am Health Drug Benefits Date: 2020-06
Authors: Olivia M Dong; Pradeep J Poonnen; David Winski; Shelby D Reed; Vishal Vashistha; Jill Bates; Michael J Kelley; Deepak Voora Journal: Value Health Date: 2021-11-01 Impact factor: 5.725
Authors: Martijn J H G Simons; Valesca P Retèl; Bram L T Ramaekers; Rogier Butter; Joanne M Mankor; Marthe S Paats; Joachim G J V Aerts; Zakile A Mfumbilwa; Paul Roepman; Veerle M H Coupé; Carin A Uyl-de Groot; Wim H van Harten; Manuela A Joore Journal: Pharmacoeconomics Date: 2021-08-18 Impact factor: 4.981
Authors: Henri B Wolff; Elisabeth M P Steeghs; Zakile A Mfumbilwa; Harry J M Groen; Eddy M Adang; Stefan M Willems; Katrien Grünberg; Ed Schuuring; Marjolijn J L Ligtenberg; Bastiaan B J Tops; Veerle M H Coupé Journal: JCO Precis Oncol Date: 2022-07
Authors: Denis Horgan; Giuseppe Curigliano; Olaf Rieß; Paul Hofman; Reinhard Büttner; Pierfranco Conte; Tanja Cufer; William M Gallagher; Nadia Georges; Keith Kerr; Frédérique Penault-Llorca; Ken Mastris; Carla Pinto; Jan Van Meerbeeck; Elisabetta Munzone; Marlene Thomas; Sonia Ujupan; Gilad W Vainer; Janna-Lisa Velthaus; Fabrice André Journal: J Pers Med Date: 2022-01-08
Authors: Raymond Henderson; Peter Keeling; Declan French; Dave Smart; Richard Sullivan; Mark Lawler Journal: Mol Oncol Date: 2021-07-19 Impact factor: 6.603